T32-supported Immunology and Rheumatology Postdoctoral Fellows will undertake two years of training in either translational research in clinical immunology or in clinical investigation. Applicants for T32 support will be M.D., Ph.D. or M.D./Ph.D. degree holders. Candidates for postdoctoral fellowships will be reviewed and selected by a Postdoctoral Committee composed of representatives of the two Rheumatology Divisions. The clinical years of postdoctoral fellowship in rheumatology for MDs, not covered by T32 funding will predominantly consist of attendance at outpatient clinics, as well as inpatient consulting. Following clinical training, trainees will select one of two Research Tracks for their T32 training: (i.) The Clinical Immunology Translational Research Track (Track 1);or (ii.) The Clinical Investigation (Track 2). The training in Track 1 will be available for those fellows interested in pursuing translational research in clinical immunology and will be supplemented with required and recommended coursework. A two-year training program in Track 2 can lead to a Master's of Science Degree, administered through the Department of Health Research and Policy. It is our belief that such formal training is important for trainees who pursue a career in clinical research, to provide a foundation in the fundamentals of clinical trial design, bioethics, data analysis, and other important issues in clinical research. For all trainees in both Tracks, attendance will be required at weekly lectures in rheumatic diseases, as well as a series of lectures on Responsible Conduct of Research. Postdoctoral trainees are expected to attend weekly Immunology Grand Rounds, Journal Club meetings, the weekly Immunology Seminar Series, and the Annual T32 and Immunology Retreats during all years of training. This will provide interactions between the rheumatology fellows and the many other immunology fellows and students involved in research endeavors at Stanford. In the T32-supported years, MD postdoctoral fellows will attend clinic one or two half-days per week, as well as regular research meetings determined by their individual preceptors. We will leverage Stanford's rich environment to provide many additional opportunities for trainees interested in immunology, proteomics, genomics, clinical trials, and outcomes.

Public Health Relevance

In order to meet future public health needs of the nation this educational training program provides exceptional research training to M.D., M.D./Ph.D., or Ph.D. trainees in adult and pediatric rheumatology and clinical immunology. It will train the next generation of translational and clinical research investigators to take advantage of new breakthroughs in understanding disease pathophysiology and the resultant potential for innovative therapy in both adult and pediatric rheumatic diseases. The long-term goal is to enable the trainees to become independent investigators and academic physician- scientist leaders of the future.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Wang, Yan Z
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Zhang, Yujuan; Gupta, Saloni; Ilstad-Minnihan, Alexandra et al. (2018) Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor. Clin Immunol 194:9-18
Favier, Leslie A; Taylor, Janalee; Loiselle Rich, Kristin et al. (2018) Barriers to Adherence in Juvenile Idiopathic Arthritis: A Multicenter Collaborative Experience and Preliminary Results. J Rheumatol 45:690-696
Kolstad, Kathleen D; Li, Shufeng; Steen, Virginia et al. (2018) Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 154:862-871
Kolstad, Kathleen D; Fiorentino, David; Li, Shufeng et al. (2018) Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. Semin Arthritis Rheum 47:865-869
Cheung, Peggie; Vallania, Francesco; Warsinske, Hayley C et al. (2018) Single-Cell Chromatin Modification Profiling Reveals Increased Epigenetic Variations with Aging. Cell 173:1385-1397.e14
Chinthrajah, R Sharon; Purington, Natasha; Andorf, Sandra et al. (2018) Development of a tool predicting severity of allergic reaction during peanut challenge. Ann Allergy Asthma Immunol 121:69-76.e2
Blum, Lisa K; Cao, Richard R L; Sweatt, Andrew J et al. (2018) Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. Eur J Immunol 48:874-884
Zhao, Yongdong; Wu, Eveline Y; Oliver, Melissa S et al. (2018) Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care Res (Hoboken) 70:1228-1237
Geraldino-Pardilla, Laura; Russo, Cesare; Sokolove, Jeremy et al. (2017) Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford) 56:534-540
Tedeschi, Sara K; Cui, Jing; Arkema, Elizabeth V et al. (2017) Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: A nested case-control study of women in the Nurses' Health Studies. Semin Arthritis Rheum 46:692-698

Showing the most recent 10 out of 59 publications